EVIDENCE-BASED CLINICAL APPROACH TO ANDROGEN SUPPRESSION AND RADIOTHERAPY IN MALE PATIENTS WITH LOCALLY ADVANCED OR LOCALIZED CARCINOMA OF THE PROSTATE

Czech version

Authors: MUDr. Vítězslav Vít; Prof. MUDr. Dalibor Pacík, CSc.
Authors‘ workplace: Urologická klinika LF MU a FN Brno pracoviště Bohunice
Published in: Urol List 2006; 4(4): 45-49

Overview

The article deals with issues of radiotherapy in the treatment of localized or locally advanced carcinoma of the prostate. The different modalities of external radiotherapy are addressed including their complications, and brachyradiotherapy as a method offering good prospects in this country is mentioned.

Also included are the options for the reduction of risk of prostate carcinoma recurrence after primary therapy with currative intention. Based on analysis of clinical studies, neoadjuvant and adjuvant hormonal deprivation is assessed for its effect on the course of prostate carcinoma after radiotherapy with currative intention.

The author's conclusion is that neoadjuvant and adjuvant androgen deprivation enhances local control of the tumour, extends the time to dissemination and increases total survival in patients after radiotherapy with currative intention.

KEY WORDS:
prostate carcinoma, radiotherapy, neoadjuvant androgen deprivation, adjuvant androgen deprivation

Sources

1. Údaje Národního onkologického registru České republiky.

2. Jemal A, Tiwari RC, Murray T et al. Statistics, 2004 Ca Cancer. J Clin 2004; 54: 8 29.

3. Hanks GE. Three-dimensional conformal radiation therapy for prostate cancer. In: D´Amico AV, Hanks GE (eds). Radiotherapeutic management of prostate adenocarcinoma. London: Arnold 1999: 21 50.

4. Hanks GE. Conformal radiotherapy for prostate ancer. Ann Med 2000; 32: 57 63.

5. Gunderson LL, Tepper JE. Clinical Radiation Oncology. New York: Churchil Livingstone 2000: 761 878.

6. Zimmerman FB, Molls M. Three-dimensional treatment planning. Principles and practice. Onkologie1998; 21: 474 484.

7. Feldmann HJ, Kneschaurek P, Molls M. Threedimensional radiation treatment. Basel: Karger 2000.

8. Fraass BA, Kessler ML, McShan LH et al. Optimization and clinical use of multisegment intensity-modulated radiation therapy for high-dose conformal therapy (review). Semin Radiat Oncol 1999; 9: 60 77.

9. Martinez A, Gonzales J, Stromberg J et al. Conformal prostate brachytherapy. Initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995; 33: 1019 1027.

10. Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR. Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database. J Urol 1998; 160: 1398 1404.

11. Koppie TM, Grossfeld GD, Miller D, Yu J, Stier D, Broering JM, Lubeck D, Henning JM, Flanders SC, Carroll PR. Patterns of treatment of patients with prostate cancer initially managed with surveillance: Results from the CaPSURE database. J Urol 2000; 164: 81 88.

12. Catalona WJ, Bigg SW. Nerve sparing radical prostatectomy. Evaluation of results after 250 patients. J Urol 1990; 143: 539 544.

13. Hering F, Rist M, Roth J et al. Does microinvasion of the capsule and/or micrometastases in regional lymph nodes influence disease-free survival after radical prostatectomy? Br J Urol 1990; 66: 177 181.

14. D´Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969 974.

15. Pilepich M, Winter K, John M et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243 1252.

16. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administred with radiatio therapy for T2 T3 prostate cancer. J Urol 2004; 171(3): 1137 1140.

17. D´Amico AV, Manola J, Lofredo M et al. 6. month androgen suppression plus radiation therapy vs radition therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821 827.

18. Denham J, Steigler A, Lamb D et al. Short-term androgen deprivation and radiotherapy for locally advance prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841 850.

19. Crook J, Ludgate C, Malone S et al. Report of multicenter Canadian phase III randomized trial of 3 months vs 8months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 15 23.

20. Horwitz EM, Winter K, Hanks GE, Byhardt RW, Russell AH, Machtay M, Pilepich MV. Long-term outcome for patients with locally advanced non-metastatic prostate cancer treated with adjuvant hormones and radiaion therapy versus radiation therapy alone: subset analysis od RTOG 85.31 and 86.10. Int J Radiat Oncol Biol Phys 1999; 45(suppl): 220 221.

21. Bolla M, Gonzales D, Warde P et al. Improved survival in patients with locally adanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295 300.

22. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103 108.

23. Roach M, Lu J, Pilepich MV et al. Predicting longterm survival and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000; 47: 617 627.

24. Wirth H, Tyrrel C, Wallace M et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localised or locally advanced prostate cancer significantly reduced risk of disease progression. Urology 2001; 58: 146 151.

25. McLeod DG, See W, Iversen P et al. Tolerability of bicalutamide (Casodex) 150mg as immediate or adjuvant therapy in 8113 men with localised or locally advanced prostate cancer. J Urol 2001; 165: 150 151.

26. Svoboda T. EPC program, přidání bicalutamidu ke standardní léčbě časného karcinomu prostaty, 3. analýza po 7,4 roku. Med Trib 2005; 19: 8 12.

Labels

Paediatric urologist Urology

WHAT'S NEW IN PROSTATE CANCER PATHOLOGY ASSESMENT IN 2006

LYMPHATIC DRAINAGE OF THE PROSTATE

PELVIC LYMPHADENECTOMY IN THE PROSTATE CARCINOMA AND ITS LIMITS

PSA AND EARLY DETECTION OF PROSTATE CARCINOMA

PATHOLOGY OF THE PROSTATE AND ANDROGEN AND ESTROGEN LEVELS

Article was published in

Urological Journal

2006 Issue 4